Monday, December 23

Tag: Moderna

Stocks Extend Post-Fed Rally – WSJ
14Dec By adminNo Comments
World

Stocks Extend Post-Fed Rally – WSJ

Updated Dec. 14, 2023 4:37 pm ETStocks extended their year-end rally. The S&P 500 rose 0.3%, Nasdaq Composite added 0.2%, Dow Jones Industrial Average was up 0.4%, closing at a new record high. Investors have recently been betting that the Fed will pivot to lowering interest rates next year, and the central bank helped confirm that view Thursday by forecasting three rate cuts in 2024. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
S&P 500, Nasdaq Extend Win Streaks
9Nov By adminNo Comments
Money

S&P 500, Nasdaq Extend Win Streaks

Major stock indexes ended mostly higher Wednesday, building on a long run of gains. The S&P 500 added 0.1%, notching an eighth-straight session in the green. The Nasdaq Composite also added 0.1%, now higher on nine consecutive days, its longest winning streak in two years. The Dow Jones Industrial Average slipped 0.1%, or 40 points.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Never Mind Covid, Investors Want a Pfizer Obesity Pill
31Oct By adminNo Comments
Money

Never Mind Covid, Investors Want a Pfizer Obesity Pill

Some of this year’s best performers in the healthcare sector are companies expected to profit from the anti-obesity drug craze, with Eli Lilly and Novo Nordisk shares both up more than 40% each. Much of the rest of the industry is underwater, with some of the biggest decliners being pandemic winners such as Pfizer and Moderna.It is little wonder, then, that investors were hoping Pfizer could jump to the winning camp with an obesity pill. But the company’s silence on its experimental oral medication, danuglipron, during its earnings release Tuesday, is worrying Wall Street. “Not one mention [of danuglipron] in the prepared remarks from Pfizer,” noted Will Sevush, a healthcare strategist for Jefferies. Before today’s earnings, David Risinger, a Leerink Partners analyst, had written that Pfi...
Read More